At Stratipath, scientific evidence is fundamental to our mission. With roots in academic research, we emphasise rigorous validation to ensure clinical accuracy. Our validity is demonstrated by significant independent studies published in renowned journals, emphasising the accuracy that earns the trust of healthcare professionals in our AI-driven precision diagnostics.
At Stratipath, scientific evidence is fundamental to our mission. With roots in academic research, we emphasise rigorous validation to ensure clinical accuracy. Our validity is demonstrated by significant independent studies published in renowned journals, emphasising the accuracy that earns the trust of healthcare professionals in our AI-driven precision diagnostics.
Stratipath Breast builds on academic research previously published in Annals of Oncology, which demonstrated the potential of AI-based risk profiling for breast cancer. Since then, multiple studies have been published, including a large validation study demonstrating the prognostic performance of Stratipath Breast.
The study, which was recently published in Breast Cancer Research and conducted by Karolinska Institutet in Stockholm, validates the prognostic performance of Stratipath Breast in a large retrospective cohort of over 2,700 patients from two independent clinical sites.
The findings showed that the Stratipath Breast analysis identified 49.6% of the clinically intermediate tumors as low risk and 50.4% as high risk. The Prosigna assay classified 32.5%, 47.0% and 20.5% tumors as low, intermediate and high risk, respectively. Among Prosigna intermediate-risk tumors, 47.3% were stratified as Stratipath low risk
This published high-impact scientific article from Karolinska Institutet shows that AI-supported image analysis can stratify intermediate-grade breast cancers into low or high risk categories This has strong prognostic value and potential to revolutionise breast pathology.
